ReNeuron Group plc

Equities

RENE

GB00BF5G6K95

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:30:01 2024-02-05 am EST			5-day change	1st Jan Change
3.375 ^GBX	-2.17%		-.--%	-3.57%

Apr. 17	ReNeuron Group Reports CFO Resignation	MT
Apr. 17	ReNeuron CFO steps down to pursue other opportunities	AN

ReNeuron reduces headcount by 40%; to focus on CustomEX data

January 19, 2023 at 09:30 am EST

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Says it has reduced its headcount by 40% following company restructuring. The company says variable costs of the business have been lowered, with the resulting cash runway now extending to 2024. ReNeuron says its focus is generating in vivo data to validate its exosome delivery technology platform, CustomEx. CustomEx is a drug delivery platform which can be optimised for specific tissue targets leading to improvements in outcome for the patient.

Chair Iain Ross says: "Strategically, the goal is to achieve the commercial validation of our CustomEX delivery platform and in order to do this we will generate in vivo data aimed at clearly differentiating our platform from that of our competitors. We aim to demonstrate the effective uptake, biodistribution and functionality of cargo delivered by CustomEX"

Current stock price: 9.36 pence, up 0.2% on Thursday

12-month change: down 77%

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about ReNeuron Group plc

ReNeuron Group Reports CFO Resignation	Apr. 17	MT
ReNeuron CFO steps down to pursue other opportunities	Apr. 17	AN
ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024	Apr. 17	CI
ReNeuron Group to Appoint Administrators	Mar. 20	MT
ReNeuron warns; Gama Aviation pledges cash return	Feb. 05	AN
ReNeuron Group Suspends Share Trading in London Amid Financial Woes	Feb. 05	MT
ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024	Jan. 30	CI
ReNeuron interim loss narrows on lower costs; eyes partnerships	Nov. 08	AN
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Revenue GBP157,000	Nov. 08	MT
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Loss GBX-5.00	Nov. 08	MT
ReNeuron Group plc Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 08	CI
ReNeuron Group Reports In Vivo Data for Exosome Delivery Platform	23-09-04	MT
ReNeuron makes progress on exosome delivery platform	23-09-04	AN
ReNeuron Group plc Auditor Raises 'Going Concern' Doubt	23-06-15	CI
Transcript : ReNeuron Group plc, 2023 Earnings Call, May 25, 2023	23-05-25
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Revenue GBP530,000	23-05-25	MT
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Loss GBX-9.50	23-05-25	MT
ReNeuron Group plc Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-25	CI
ReNeuron Group plc Announces New Scientific Advisory Board	23-04-03	CI
FTSE 100 Closes Down 1.1% as Early Year Optimism Runs Into Turbulence	23-01-19	DJ
ReNeuron reduces headcount by 40%; to focus on CustomEX data	23-01-19	AN
Sterling Could Fall as BOE Stays Cautious	23-01-19	DJ
UK House Prices Falling Faster than Expected - RICS	23-01-19	DJ
UK Housebuilders Fall as Market Hits Weakest Since 2010	23-01-19	DJ
ReNeuron Cuts Headcount by 40%, Lowers Variable Costs in Restructuring Effort	23-01-19	MT

Chart ReNeuron Group plc

Duration

Period

More charts

Company Profile

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Companyâs CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Sector

Biotechnology & Medical Research

Calendar

2024-07-10 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RENEURON GROUP PLC	-3.57%	2.4M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research